ERBB2 and breast carcinoma: The addition of a CD36 inhibitor might boost the anti-proliferation effects of PI3K therapeutics in anti-HER2 resistant, PTEN-loss breast cancer cells, thus providing promising insights for the development of combination regimens based on approved PI3K inhibitors with a tolerable toxicity profile.